| payload |
{"created_at":"2026-04-03T11:12:58.166 {"created_at":"2026-04-03T11:12:58.166696+00:00","dedupe_key":"signal_enriched:discovery_new_listings_delta:5540356a5b93ebd3","evidence_event_ids":["evt_e708d6bc5596"],"signal_type":"discovery_new_listings_delta","source":"discovery_ingestor","value":{"aggregator_url":"https://www.nasdaq.com/articles/cantor-fitzgerald-initiates-coverage-pelthos-therapeutics-pths-overweight-recommendation","as_of":"2026-04-03T11:12:58.166696+00:00","canonical_url":"https://www.nasdaq.com/articles/cantor-fitzgerald-initiates-coverage-pelthos-therapeutics-pths-overweight-recommendation","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/cantor-fitzgerald-initiates-coverage-pelthos-therapeutics-pths-overweight-recommendation","article_chars":3921,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_b6d0c0bab5110731","canonical_host":"nasdaq.com","canonical_is_aggregator":false,"canonical_url":"https://www.nasdaq.com/articles/cantor-fitzgerald-initiates-coverage-pelthos-therapeutics-pths-overweight-recommendation","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-04T00:14:19.391048+00:00","extraction_method":"heuristic","fetched_description":"Fintel reports that on April 1, 2026, Cantor Fitzgerald initiated coverage of Pelthos Therapeutics (NYSEAM:PTHS) with a Overweight recommendation. Analyst Price Forecast Suggests 191.67% Upside","fetched_title":"Cantor Fitzgerald Initiates Coverage of Pelthos Therapeutics (PTHS) with Overweight Recommendation | Nasdaq","final_url":"https://www.nasdaq.com/articles/cantor-fitzgerald-initiates-coverage-pelthos-therapeutics-pths-overweight-recommendation","html_truncated":false,"paywall_likely":false,"publisher_domain":"nasdaq.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/cantor-fitzgerald-initiates-coverage-pelthos-therapeutics-pths-overweight-recommendation","source_event_id":"evt_e708d6bc5596","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"1c901255c802e7ff","kind":"new_listings","published_at":"2026-04-03T00:04:48+00:00","publisher_domain":"nasdaq.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.9,"dates_mentioned":["2026-04-01","2026-03-27"],"entities":[{"asset_class":"equity","name":"Pelthos Therapeutics","relevance":"primary","symbol":"PTHS","type":"company"}],"event_type":"listing","information_gaps":["No details on the specific reasons for the Overweight recommendation are provided.","No information on the current market conditions affecting PTHS is mentioned."],"key_facts":["Cantor Fitzgerald's price forecast suggests a 191.67% upside from the latest closing price of $20.40/share.","Projected annual revenue for Pelthos Therapeutics is $66 million, an increase of 291.78%.","Total shares owned by institutions increased by 94.35% to 899K shares in the last three months."],"numeric_claims":[{"label":"Projected price target increase","value":"191.67%"},{"label":"Projected annual revenue","value":"$66 million"},{"label":"Total shares owned by institutions increase","value":"94.35%"}],"primary_claim":"Cantor Fitzgerald initiated coverage of Pelthos Therapeutics (PTHS) with an Overweight recommendation on April 1, 2026.","relevance_score":0.85,"sentiment":"positive","source_quality":"high","summary":"Cantor Fitzgerald has initiated coverage of Pelthos Therapeutics (PTHS) with an Overweight recommendation, projecting a 191.67% upside based on an average price target of $59.50 per share.","topics":["investment","analyst coverage","price target"]},"source":"Nasdaq Stocks","source_domain":"nasdaq.com","summary":"Fintel reports that on April 1, 2026, Cantor Fitzgerald initiated coverage of Pelthos Therapeutics (NYSEAM:PTHS) with a Overweight recommendation. Analyst Price Forecast Suggests 191.67% Upside","tickers":["PTHS"],"title":"Cantor Fitzgerald Initiates Coverage of Pelthos Therapeutics (PTHS) with Overweight Recommendation","url":"https://www.nasdaq.com/articles/cantor-fitzgerald-initiates-coverage-pelthos-therapeutics-pths-overweight-recommendation"}}... |